Visceral fat XXXX is highly associated with @entity210 in a metabolically obese but normal weighted population: a case control study.

@entity1 @entity32 @entity28 @entity1674 @entity412 @entity5052 @entity209 @entity210 @entity413
INTRODUCTION: Gout is a chronic @entity32 the development of which is associated with @entity28 -induced @entity209 . However, a substantial number of @entity28 @entity1 (body mass index [BMI] <25  kg/m(2)) also develop @entity210 in Korea. It was suggested that accumulation of visceral fat rather than subcutaneous fat is associated with @entity209 and @entity5052 in @entity1 with @entity210 ; therefore, we hypothesized that visceral fat accumulation was @entity28 @entity1 . METHODS: One hundred and three male @entity1 with @entity210 and 204 age-matched healthy controls who attended a health check-up examination were recruited after the review of medical charts. The visceral fat area (VFA) was measured using the bioelectrical impedance analysis (BIA) method, and a VFA >100  cm(2) was defined as visceral fat @entity28 (VFO). The frequency of VFO was compared in @entity1 and control groups. The frequencies of @entity209 and related parameters were also investigated. RESULTS: BMI, waist circumference, total fat mass, serum @entity1674 , and serum @entity413 levels were significantly greater in @entity1 compared with controls. VFA and the prevalence of VFO was increased in @entity210 @entity1 compared with controls. There were positive correlations between VFA and serum @entity412 levels and serum @entity413 levels. Multivariate regression analysis revealed that VFO is an independent risk factor for @entity210 (odds ratio 2.488, 95% confidence interval 1.041-4.435). In @entity28 subgroup analyses ( @entity210 @entity1 , n   =   38; healthy controls, n   =   150), VFA (98.7        19.3 vs. 91.0        16.7, P   =   0.016) and the frequency of VFO (47.4 vs. 27.3%, P   =   0.017) remained significantly higher in @entity210 @entity1 . There was no difference in either BMI or total fat mass between @entity1 and controls in the @entity28 subgroup. The prevalence of @entity209 in @entity1 with @entity210 was 31.7% (33/104), compared with 13.2% (5/38) in the @entity28 subgroup according to modified ATP III criteria. CONCLUSION: VFO, measured using BIA, is observed more frequently in @entity1 with @entity210 compared with healthy controls, even in @entity28 individuals. Therefore, VFO might more properly represent metabolic derangements in @entity1 with @entity28 .
